about
Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice.The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injuryThrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in miceFas-induced apoptosis increases hepatocyte tissue factor procoagulant activity in vitro and in vivo.Toxicogenomic analysis reveals profibrogenic effects of trichloroethylene in autoimmune-mediated cholangitis in miceCoagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice.Hepatocyte tissue factor activates the coagulation cascade in miceRNA Sequencing Identifies Novel Translational Biomarkers of Kidney Fibrosis.Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanismRole of hemostatic factors in hepatic injury and disease: animal models de-liver.Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease.Developmental abnormalities in chicken embryos exposed to N-nitrosoatrazine.Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte αMβ2 integrin-dependent upregulation of Mmp12.Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.Targeting Phospholipase D4 Attenuates Kidney Fibrosis.Alveolar Macrophages.Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.Von Willebrand factor deficiency reduces liver fibrosis in mice.Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis
P50
Q33424466-2EA0A107-1EF6-4D2C-A6B6-FC11F1C0C41EQ33603645-3344FF1F-B4D6-4435-8A49-C4ECA28448A7Q34360710-9934628F-66E5-4F3C-B397-CA3620060CDBQ34736260-2BA7D9A6-EC8E-45A3-9A37-27364EEF9B6AQ34736314-8C1D41D2-53E8-42D6-81CA-82EFC7ABDB49Q35806023-CC397DDF-EEA0-4FB0-B472-68181F8CCCA1Q36666812-C42FC179-748D-4C4C-A1EC-168865470C9FQ36944655-3828C43F-23CF-4EA6-B42F-8ADE759BBF2AQ36965875-FDEF22CF-D1B2-4DC8-A27B-43DC09623450Q37387653-D6BE518B-765C-4A0E-BB35-607E7F890A65Q37387670-65A01D7F-F73F-4E31-A31D-AB6861FB9131Q45743491-72185E3F-2D7A-4925-8A16-F60331EC5F1FQ46446477-B740A214-BA47-4D96-9C46-42509A6F5638Q47147995-787CCB76-F815-41B7-B066-7815FC138B25Q47939968-6C937D50-F482-4CA7-AC0D-BCAF2FB5A715Q47944492-5643FBA0-8710-445E-B331-733D380E74CDQ49686389-75415B5B-5445-4038-8D3C-A94CC0280A60Q50142593-6B7841EF-E475-407B-859E-ED546285D29EQ50206717-49CBCB5F-D250-4324-B9FD-DBEB8F080852Q90565414-0E29932F-BB44-4738-9DEE-D2061EB374CE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nikita Joshi
@ast
Nikita Joshi
@en
Nikita Joshi
@es
Nikita Joshi
@nl
type
label
Nikita Joshi
@ast
Nikita Joshi
@en
Nikita Joshi
@es
Nikita Joshi
@nl
prefLabel
Nikita Joshi
@ast
Nikita Joshi
@en
Nikita Joshi
@es
Nikita Joshi
@nl
P106
P1153
55657539100
P31
P496
0000-0001-8330-0663